Cargando…
Anti-apoptotic BCL-2 proteins govern cellular outcome following B-RAF(V600E) inhibition and can be targeted to reduce resistance
In theory, pharmacological inhibition of oncogenic signaling is an effective strategy to halt cellular proliferation, induce apoptosis, and eliminate cancer cells. In practice, drugs (e.g., PLX-4032) that inhibit oncogenes like B-RAF(V600E) provide relatively short-term success in patients, due to a...
Autores principales: | Serasinghe, Madhavika N., Missert, Derek J., Asciolla, James J., Wieder, Shira Y., Podgrabinska, Simona, Izadmehr, Sudeh, Belbin, Gillian, Skobe, Mihaela, Chipuk, Jerry E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4160434/ https://www.ncbi.nlm.nih.gov/pubmed/24608435 http://dx.doi.org/10.1038/onc.2014.21 |
Ejemplares similares
-
Activation of the Mitochondrial Fragmentation Protein DRP1 Correlates with BRAF(V600E) Melanoma
por: Wieder, Shira Y., et al.
Publicado: (2015) -
Born to be Alive: A Role for the BCL-2 Family in Melanoma Tumor Cell Survival, Apoptosis, and Treatment
por: Anvekar, Rina A., et al.
Publicado: (2011) -
Putting the pieces together: How is the mitochondrial pathway of apoptosis regulated in cancer and chemotherapy?
por: Elkholi, Rana, et al.
Publicado: (2014) -
Sensitization to the mitochondrial pathway of apoptosis augments melanoma tumor cell responses to conventional chemotherapeutic regimens
por: Anvekar, R A, et al.
Publicado: (2012) -
Dual suppression of inner and outer mitochondrial membrane functions augments apoptotic responses to oncogenic MAPK inhibition
por: Serasinghe, Madhavika N., et al.
Publicado: (2018)